Full-Time

Global Studies Asset Manager

Gsam

Posted on 9/30/2025

Deadline 10/14/25
Roche

Roche

1-10 employees

Global pharmaceuticals and diagnostics company

No salary listed

Mississauga, ON, Canada

In Person

Relocation Benefits are not available for this job posting.

Category
Medical, Clinical & Veterinary (1)
Required Skills
Supply Chain Management
Google Cloud Platform
Requirements
  • 5-7 years' of relevant operations experience
  • Undergraduate degree or equivalent years of experience, preferred focus in life sciences
  • Strong working knowledge of drug development process and respective regulations, including ICH and GCP guidelines
  • Self-starter who finds passion in achieving successful outcomes
  • Desire to make a difference and excitement in innovating practices, products and processes
  • Growth mindset and excitement about learning through experience
  • Comfortable thinking on your feet and thriving in fast-paced, ambiguous and highly collaborative environments
Responsibilities
  • Co-ordinate and deliver the study management aspects of a group of studies within an asset’s portfolio following IHC-GCP and Roche processes in accordance SOPs and guidelines to ensure the clinical study progresses as planned
  • Provide input into the development of essential study level documents (eg study protocol, TMP, Pharmacy manual)
  • Develops a study's recruitment expectations in partnership with APO, Roche countries and the partner CRO and develops and maintains a forecast using the appropriate systems (EFT)
  • Develop and/or maintain or provide input in collaboration with CRO partners, study management essential documents (EG Pharmacy manual, relevant study plans/ relevant training materials (EG IMP management))
  • Drive innovation in clinical operations by thinking of and contributing to the implementation of new approaches in partnership with COE, APO and HBS in order to deliver outcomes that meet and exceed industry best practices
  • Build and role model effective study partnership behaviors and mindsets with your TA aligned CRO partner to ensure we maximize the expertise of the CRO and our internal colleagues, minimising duplication of work and ensuring cost and resource efficiency for study(ies) in responsibility
  • Develop and oversee key performance indicators (KPIs, quality and operational) for areas of responsibility by using company tracking systems and proactively communicating any risks to timelines and/or quality, or identified quality issues, along with proposed mitigations to your Global Studies Leader
  • Maintain inspection readiness of the relevant components in scope of responsibility
  • Lead 3rd party vendor selection Vendor identification set up, and oversight and close out to ensure delivery to contract (in line with relevant iCOP strategies and study level needs)
  • Produce, arrange translation & distribute patient and site facing support materials
  • Management supply and shipment of IMP
  • Obtain and distribute clinical trial insurance
  • Regularly seek and provide feedback to study team members on their individual performance to support their professional development and contribute to the achievement of a High Performing Organization.
Desired Qualifications
  • Prior clinical trial management

Roche is a global leader in pharmaceuticals and diagnostics. It develops medicines and diagnostic tools that help detect, monitor, and treat diseases, using research and biotechnology to drive new therapies and tests. Roche combines drug development with in-house diagnostic products to support personalized medicine, where treatments are tailored to individual patients based on test results. Its approach differs from many peers by integrating drug discovery with diagnostic capabilities and by expanding its research through strategic acquisitions (like Genentech) to strengthen its biotechnology and R&D capabilities. The company’s goal is to improve patient outcomes and healthcare worldwide by delivering reliable medicines, accurate diagnostic tests, and data-driven care.

Company Size

1-10

Company Stage

IPO

Headquarters

Basel, Switzerland

Founded

1896

Simplify Jobs

Simplify's Take

What believers are saying

  • PathAI can strengthen AI pathology workflows and biomarker discovery.
  • Elecsys pTau217 expands Roche's Alzheimer diagnostics beyond specialist laboratory settings.
  • Nurix collaboration deepens Roche's reach into protein degradation and hematology.

What critics are saying

  • Swiss franc strength keeps distorting reported growth and investor perception.
  • Patent expirations on older medicines force rapid replacement from newer assets.
  • CT-388 must beat Novo Nordisk and Eli Lilly to matter.

What makes Roche unique

  • Roche combines pharmaceuticals, diagnostics, and digital pathology across one healthcare platform.
  • Founded in Basel in 1896, Roche built scale through branded medicines.
  • Genentech integration made Roche the world's largest biotechnology company.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Roche who can refer or advise you

Benefits

Performance Bonus

Company News

Dealroom.co
Apr 16th, 2026
SAGA company information, funding & investors

SAGA, providing cancer companion diagnostic testing of tissue and non-invasive monitoring of circulating tumor dna (ctdna). Here you'll find information about their funding, investors and team.

Yahoo Finance
Apr 13th, 2026
Roche receives CE mark for Elecsys NfL blood test to detect neuroinflammation in multiple sclerosis

Roche has received CE mark approval for its Elecsys Neurofilament Light Chain blood test to detect neuroinflammation in adults with relapsing remitting multiple sclerosis. The test measures NfL, a protein released during nerve cell injury, providing insight into neuroaxonal damage associated with the disease. Multiple sclerosis affects over 2.9 million people worldwide. Whilst early and regular monitoring is critical, patients often struggle to access routine MRI scans. The minimally invasive blood test offers a more accessible alternative, complementing clinical assessments and potentially enabling earlier intervention. The test runs on Roche's widely available cobas instruments, delivering standardised results and requiring only a simple blood sample. This reduces the need for patients to travel to specialist centres, making frequent monitoring more practical where traditional testing faces geographic, financial or logistical barriers.

Bizwatch
Apr 12th, 2026
Roche invests $20M in degrader-antibody conjugate platform via C4 Therapeutics deal worth up to $1B

Roche has partnered with C4 Therapeutics to develop degrader-antibody conjugates (DACs), marking a $20 million upfront payment with potential milestone payments exceeding $1 billion. The collaboration targets cancer therapeutics using C4's Torpedo platform. DACs represent a next-generation approach to antibody-drug conjugates (ADCs). Whilst ADCs attach cytotoxic drugs to antibodies, DACs use targeted protein degradation payloads to selectively eliminate specific proteins within cancer cells, potentially reducing toxicity and drug resistance whilst accessing previously difficult targets. Amongst Korean listed companies, Orum Therapeutics leads DAC development, having licensed ORM-6151 to Bristol Myers Squibb in 2023. Y-Biologics partnered with Ubix Therapeutics, whilst Oscotec is developing three DAC pipelines through subsidiary Genosco, targeting technology transfers after 2028.

Yahoo Finance
Mar 30th, 2026
Roche gets FDA clearance for cobas c703 and ISE neo lab testing units with 2,000 tests per hour

Roche has received FDA 510(k) clearance for its cobas c703 and cobas ISE neo analytical units, designed to enhance laboratory efficiency through increased automation and testing capacity. The units are part of Roche's cobas pro integrated solutions platform. The cobas c703 delivers up to 2,000 tests per hour with 70 reagent positions, doubling clinical chemistry throughput whilst reducing reagent reloads. The cobas ISE neo provides up to 1,800 tests per hour with automated maintenance, reducing hands-on time and plastic waste compared to previous systems. Both units feature monthly operator maintenance to improve uptime and help laboratories address staffing shortages and growing test volumes. Roche has over 4,000 cobas analysers installed across the United States.

Yahoo Finance
Mar 30th, 2026
Roche launches cobas MPX-E assay, 4-in-1 donor screening test for HIV, HCV, HBV and HEV

Roche has launched the cobas MPX-E assay, a four-in-one donor screening test that simultaneously detects HIV, Hepatitis C, B and E viruses. The test is now available in countries accepting the CE mark. The assay consolidates detection of four major viral targets into a single workflow, improving laboratory efficiency and reducing costs. It features dual-target detection for HIV-1 and enhanced sensitivity for Hepatitis E, which causes an estimated 20 million infections and 70,000 deaths annually worldwide. The test runs on Roche's fully automated cobas x800 systems, which process over 10 million tests monthly across laboratories globally. The ready-to-load reagents enable up to eight hours of walk-away time. The nucleic acid testing blood screening market is valued at approximately 800 million Swiss francs globally, with an expected annual growth rate of 2% through 2029.

INACTIVE